Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer

NCT00693719 is registered in ClinicalTrials.gov with University of Arizona as lead sponsor.

NCT NCT00693719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00693719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study: Irinotecan and Etoposide as Treatment for Refractory, Metastatic Breast Cancer
Lead sponsor
University of Arizona
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
May 31, 2013
Enrollment
31 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer